Opaleye Management’s Steady Buying Signals Confidence in Sol‑Gel’s Undervalued Dermatology Pipeline
Opaleye’s steady buy‑in of Sol‑Gel Technologies shares suggests hidden value in its dermatology pipeline, offering a hopeful yet volatile investment angle.
3 minutes to read